Latest News

Pfizer applies for FDA authorization for Omicron-retooled vaccine booster in kids under 5


(Reuters) – Pfizer and its German partner BioNTech said on Dec. 4 they have submitted an application to the U.S. Food and Drug Administration for emergency use authorization of their Omicron-adapted COVID-19 vaccine booster for children aged 6 months through 4 years.

If authorized, children would receive the primary series consisting of two doses of the original Pfizer-BioNTech COVID vaccine and one shot of the Omicron-adapted bivalent vaccine, the company said.

The bivalent COVID-19 vaccine, which targets the original strain and the BA.4/BA.5 Omicron subvariants, is currently authorized as a booster dose for ages 5 years and older in the United States and the European Union.

Last month, a real-world study of more than 360,000 people in the United States found the updated bivalent boosters, including those of rival Moderna, offered increased protection against new coronavirus subvariants in people who have received up to four doses of the older vaccine.

Reuters Health Information © 2022

Recommended Reading

U.S. flu activity already at mid-season levels
MDedge Pediatrics
Covid vax prevents death in children regardless of variant
MDedge Pediatrics
Buzzy Lancet long COVID paper under investigation for ‘data errors’
MDedge Pediatrics
RSV surge stuns parents and strains providers, but doctors offer help
MDedge Pediatrics
FDA pulls U.S. authorization for Eli Lilly’s COVID drug bebtelovimab
MDedge Pediatrics